Constanza Silvestrini

Constanza Silvestrini

Auto-generated profile, based on publicly available information

Constanza Silvestrini

Department of Health Technology Assessment and Health Economics, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2024 in Public Health
Verified
Journal Article
Open access
AAA. Alcaraz
A. Alcaraz
FCFederico Rodriguez Cairoli
Federico Rodriguez Cairoli
CCC. Colaci
C. Colaci
CSC. Silvestrini
C. Silvestrini
CGC. Gabay
C. Gabay
EEEspinola Espinola
Espinola Espinola
Lung cancer remains a significant global public health challenge and is still one of the leading causes of cancer-related death in Argentina. This study aims to assess the disease and economic burden of lung cancer in the country. Burden of disease study. A mathematical model was developed to estimate the disease burden and direct medical cost attributable to lung cancer. Epidemiological parameters were obtained from local statistics, the Global Cancer Observatory, the Global Burden of Disease databases, and a literature review. Direct medical costs were estimated through micro-costing. Costs were expressed in US dollars (US$), April 2023 (1 US$ = 216.38 Argentine pesos). A second-order Monte Carlo simulation was performed to estimate the uncertainty. Considering approximately 10,000 deaths, 12,000 incident cases, and 14,000 5-year prevalent cases, the economic burden of lung cancer in Argentina in 2023 was estimated to be US$ 556.20 million (396.96-718.20), approximately 1.4% of the total healthcare expenditure for the country. The cost increased with a higher stage of the disease, and the main driver was drug acquisition (80%). A total of 179,046 disability-adjusted life years could be attributable to lung cancer, representing 10% of the total cancer. The disease and economic burden of lung cancer in Argentina implies a high cost for the health system and would represent 19% of the previously estimated economic burden for 29 cancers in Argentina.

30 January 2025 in Expert Review of Pharmacoeconomics & Outcomes Research
Verified
Journal Article
Closed access
CSConstanza Silvestrini
Constanza Silvestrini
LPLucas Perelli
Lucas Perelli
AAAndrea Alcaraz
Andrea Alcaraz
EEEspinola Espinola
Espinola Espinola
FAFernando Argento
Fernando Argento
Lung cancer (LC) is a leading cause of cancer mortality in Argentina. Low-dose computed tomography (LDCT) had demonstrated higher efficacy than chest radiography as a screening method for early detection and reducing LC mortality. This study estimates the Budget Impact of implementing annual LDCT screening for individuals aged 55-74 with at least 30 pack-years of smoking in Argentina. A budgetary impact model for a dynamic cohort was developed from the Argentine health system's perspective, accounting for LC incidents, prevalents and death probability, distinguishing by disease stage and survival years. Model parameters were sourced from literature and official databases, with costs expressed in 2023 USD. In Argentina, 726,420 individuals were eligible for annual LC screening. The average annual budget was USD 196,611,452 in the current scenario and USD 207,439,560 in the projected scenario, leading to a 5.20% incremental cost due to more false positives in LDCT and screening costs. The budget impact per member per month was USD 0.019, slightly above the estimated threshold of USD 0.015. The introduction of LDCT for LC screening increased the health system budget in Argentina but improved early disease detection.

13 July 2024 in PharmacoEconomics - Open
Verified
Journal Article
Open access
PDF file
EEEspinola Espinola
Espinola Espinola
CSConstanza Silvestrini
Constanza Silvestrini
CCCarla Colaci
Carla Colaci
DSDaniela Sugg
Daniela Sugg
CRCarlos Rojas Roque
Carlos Rojas Roque
FAFederico Augustovski
Federico Augustovski
Objectives The aim of this study was to perform a budget impact analysis (BIA) of introducing olaparib treatment for adult patients with metastatic castration-resistant prostate cancer in Argentina. Methods A BIA model was used to estimate the cost difference between the current scenario (without olaparib) and the new scenario (incorporation of olaparib) for a third-party payer over a 5-year time horizon. The budgetary impact is estimated at the national health system level and by healthcare sectors in Argentina. Input parameters were obtained from the literature and validated by local expert opinion. Direct medical costs were obtained from both the Institute for Clinical Effectiveness and Health Policy (IECS) unit cost database and public data in Argentina. The microcosting estimation was used for key variables of the analysis. All costs are reported in US dollars (US$) as for October 2022 (1 US$ = 152.59 Argentine pesos). One-way sensitivity analyses and scenario analyses were conducted to evaluate the model robustness. Results The incorporation of olaparib, with a wholesale price per pack of US$3176, was associated with a weighted average of the budget impact per member per month (PMPM) of US$0.0191 for the national health system, being slightly higher than the estimated budgeted high impact threshold (US$0.0153). The PMPM budget impact for a 5-year average ranged between US$0.007 (public sector) and US$0.033 (private sector). The duration of treatment with olaparib was the most influential parameter in the budget impact results. Conclusions The introduction of olaparib for the treatment of metastatic castration-resistant prostate cancer has a high budget impact for Argentina's health system. These findings are informative to support policy decisions aimed to expand the current treatment landscape for prostate cancer.

3 June 2024 in PharmacoEconomics - Open
Verified
Journal Article
Open access
PDF file
CRCarlos Rojas Roque
Carlos Rojas Roque
CSConstanza Silvestrini
Constanza Silvestrini
FAFernando Argento
Fernando Argento
DSDaniela Sugg
Daniela Sugg
FAFederico Augustovski
Federico Augustovski
EEEspinola Espinola
Espinola Espinola
Objectives To perform a budget impact analysis (BIA) of introducing olaparib as maintenance therapy in women who have BRCA mutations (BRCAm) with platinum-sensitive recurrent ovarian cancer (PSROC) in combination with bevacizumab in Argentina. Methods A BIA model was used to analyse over a 5-year time horizon the change in the health system’s budget following the adoption of olaparib as maintenance therapy in BRCAm patients with PSROC. The BIA for each year was estimated by comparing the cost difference between the current scenario (treatment with bevacizumab) and the new scenario (the addition of olaparib) for a third-party payer. The BIA is estimated at the national health system level, and by healthcare sectors in Argentina (public sector, social security and private sector). International and national epidemiological data were used to determine the target patient population. Clinical efficacy, safety outcomes and duration of treatments were obtained from the pivotal clinical study report. Relevant direct medical costs were obtained from public data in Argentina and expert consultation. All the costs are reported in US dollars as of October 2022 ($1 = 152.59 Argentine pesos). A scenario analysis assessed the full coverage of the homologous recombination deficiency (HRD) test in Argentina. In addition, one-way sensitivity analysis was conducted to evaluate the model robustness. Results For a third-party payer with a cohort of 1,000,000 women covered, the estimated target population was 2 individuals in year 1 and 6 individuals in year 5. The incorporation of olaparib, with a wholesale price per pack of $3176.32, was associated with a weighted average of the budget impact per member per month (PMPM) of $0.062 for the national health system, being above the estimated health system budget impact threshold ($0.0153). By healthcare sector, the results of budget impact PMPM for year 5 ranged between $0.08 (public sector) and $0.114 (private sector). For all perspectives, the variables that most influenced the budget impact was the incidence of ovarian cancer, the drug acquisition cost and the treatment duration. Conclusions The introduction of olaparib for the treatment of BRCAm women with PSROC has a high budget impact for all three health systems in Argentina.

10 October 2023 in arXiv
Verified
Preprint
Open access
PDF file
AAAndrea Alcaraz
Andrea Alcaraz
FCFederico Rodriguez Cairoli
Federico Rodriguez Cairoli
CCCarla Colaci
Carla Colaci
CSConstanza Silvestrini
Constanza Silvestrini
CGCarolina Gabay
Carolina Gabay
EEEspinola Espinola
Espinola Espinola
Objectives: Lung cancer remains a significant global public health challenge and is still one of the leading cause of cancer-related death in Argentina. This study aims to assess the disease and economic burden of lung cancer in the country. Study design: Burden of disease study Methods. A mathematical model was developed to estimate the disease burden and direct medical cost attributable to lung cancer. Epidemiological parameters were obtained from local statistics, the Global Cancer Observatory, the Global Burden of Disease databases, and a literature review. Direct medical costs were estimated through micro-costing. Costs were expressed in US dollars (US$), April 2023 (1 US$ =216.38 argentine pesos). A second-order Monte Carlo simulation was performed to estimate the uncertainty. Results: Considering approximately 10,000 deaths, 12,000 incident cases, and 14,000 5-year prevalent cases, the economic burden of lung cancer in Argentina in 2023 was estimated to be US$ 556.20 million (396.96 -718.20), approximately 1.4% of the total healthcare expenditure for the country. The cost increased with a higher stage of the disease and the main driver was the drug acquisition (80%). 179,046 Disability-adjusted life years could be attributable to lung cancer representing the 10% of the total cancer. Conclusion: The disease and economic burden of lung cancer in Argentina implies a high cost for the health system and would represent 19% of the previously estimated economic burden for 29 cancers in Argentina.

28 February 2026 in Vaccines
Verified
Journal Article
Open access
PDF file
LPLeandro Javier Pastori
Leandro Javier Pastori
CVConstanza Silvestrini Viola
Constanza Silvestrini Viola
TATomas Alconada
Tomas Alconada
GPGonzalo Pereira
Gonzalo Pereira
JMJose Luis Montes
Jose Luis Montes
EEEspinola Espinola
Espinola Espinola
Background: Influenza imposes a substantial burden on Argentina, particularly among adults aged 50–64 with comorbidities and those aged ≥65. The adjuvanted trivalent influenza vaccine (aTIV) has shown superior effectiveness compared with non-adjuvanted vaccines; however, its cost-effectiveness and budget impact in the 50–64 high-risk population have not been assessed nationally. This study evaluates the cost-effectiveness and budget impact of introducing aTIV for high-risk adults aged 50–64, alongside its use in adults aged ≥65, compared with standard-dose trivalent influenza vaccine (SD-TIV) from the Argentine health care system perspective. Methods: A decision-analytic static model was used to compare aTIV with SD-TIV over a single influenza season. In addition, a 5-year budget impact analysis (BIA) was conducted under scenarios of progressive uptake. Model inputs were derived from international literature, local data, and expert opinion. Deterministic and probabilistic sensitivity analyses were performed. Results: Compared with SD-TIV, aTIV yielded a lifetime gain of 1489 quality-adjusted life-years (QALYs) at an incremental cost of USD 8.34 million, resulting in an incremental cost-effectiveness ratio (ICER) of USD 5599 per QALY gained—well below Argentina’s cost-effectiveness threshold (USD 11,059/QALY). Higher vaccine acquisition costs were largely offset by reductions in outpatient visits and hospitalizations. The BIA showed a modest average annual per-member-per-month increase of USD 0.0025, remaining below the estimated budget impact threshold (USD 0.0065). Conclusions: Implementing aTIV in adults aged ≥50 with risk factors would be cost-effective and affordable in Argentina. These findings support the consolidation and potential expansion of current vaccination strategies to reduce influenza burden.